Type of information: Series B financing round
Company: Taris Biomedical (USA - MA)
Investors: BMS (USA - NY) Flagship Pioneering (USA - MA) Norma Investments (UK) Polaris Partners (USA - MA) RA Capital Management (USA - MA) Yonghua Capital (China)
Amount: $ 25 million
Funding type: series B financing round
- Taris Biomedical has entered into a clinical research collaboration with BMS to study the combination of Opdivo®
(nivolumab) and its lead program TAR-200 (GemRIS™) in the treatment of muscle invasive bladder cancer. The company is developing two lead programs in bladder cancer and overactive bladder. Funds from this round will be used to rapidly advance both indications through key clinical milestones.
- • On December 21, 2017, Taris Biomedical announced that it has raised $25M in a Series B financing. This round was led by Yonghua Capital, with participation from new investors BMS and Norma Investments, representing businessman Roman Abramovich. Existing investors Flagship Pioneering, Polaris Partners, and RA Capital Management, also participated in the Series B round.
Therapeutic area: Cancer - Oncology